894400-24-9

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 540-37-4 p-aminoiodobenzene 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 894401-16-2 N-(cyclopropylmethyl)-N-(4-iodophenyl)pyrimidin-2-amine 
• 894400-55-6 N-benzyl-N-(4-iodophenyl)pyrimidin-2-amine 
• 894401-12-8 N-(4-iodophenyl)-N-(3-methyl-2-butenyl)pyrimidin-2-amine 
• 894400-31-8 N-(4-iodophenyl)-N-methyl-2-pyrimidinylamine 
• 894401-24-2 N-(4-iodophenyl)-N-propylpyrimidin-2-amine 
• 894401-20-8 N-(4-iodophenyl)-N-isobutylpyrimidin-2-amine 
• 894400-35-2 N-(4-iodophenyl)-N-ethylpyrimidin-2-amine 
• 894400-43-2 N-(4-iodophenyl)-N-isopropylpyrimidin-2-amine 
• 894400-51-2 3-(N-(4-iodophenyl)-N-(pyrimidin-2-yl)amino)propanenitrile 
• 894400-47-6 (4-acetoxybenzyl)-(4-iodophenyl)pyrimidin-2-ylamine 
• 894400-39-6 N-(4-iodophenyl)-N-(2-methoxyethyl)pyrimidin-2-amine 
• 894404-68-3 (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(methyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid methyl ester 
• 894402-61-0 (E)-2-(2,6-dichlorobenzamido)-5-[4-(methyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid methyl ester 
• 894404-77-4 (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid methyl ester 

Relevant academic research and scientific papers

Multiple Roles of the Pyrimidyl Group in the Rhodium-Catalyzed Regioselective Synthesis and Functionalization of Indole-3-carboxylic Acid Esters

A regioselective synthesis of indole-3-carboxylic acid esters from anilines and diazo compounds has been realized by making use of the pyrimidyl group-assisted rhodium-catalyzed C-H activation and C-N bond formation. The reaction proceeds under mild conditions, exhibits good functional group tolerance and scalability. Reutilization of the pyrimidyl directing group in the resulting products provided an efficient strategy for further C-7 functionalization of indoles. Moreover, the pyrimidyl moiety could be readily removed as a leaving group to offer various free N-H indoles.

N-(jodoethane phenylpropionic) Pirimidinyl production of amine derivative

PROBLEM TO BE SOLVED: To suppress generation of byproducts so as to improve production efficiency and purification efficiency of an N-(iodophenyl)pyrimidinylamine derivative, when producing the N-(iodophenyl)pyrimidinylamine derivative. SOLUTION: Th

Hypervalent iodine(III) promoted direct synthesis of imidazo[1,2-a] pyrimidines

An efficient and mild synthesis of imidazo[1,2-a]pyrimidine derivatives has been developed from readily available pyrimidyl arylamines or enamines through a hypervalent iodine-promoted intramolecular C-H bond cycloamination reaction. This protocol allows for the facile construction of biologically active bicyclic imidazo[1,2-a]pyrimidine skeletons as well as other imidazo[1,2-a]-type fused heterocycles.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA

A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS

A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.

GLYCINE DERIVATIVE AND USE THEREOF

The compounds in the present invention, for example, the compound represented by the formula: has an excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo stability when administered orally in comparison with conventional compounds. That is, the compounds can be administered orally, and can have excellent therapeutic or prophylactic effect sustained for a longer period of time.

GLYCINE DERIVATIVE AND USE THEREOF

A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.